The PI3K/Akt Pathway and Glucose Metabolism: A Dangerous Liaison in Cancer

被引:19
|
作者
Fontana, Fabrizio [1 ]
Giannitti, Gaia [1 ]
Marchesi, Sara [1 ]
Limonta, Patrizia [1 ]
机构
[1] Univ Milan, Dept Pharmacol & Biomol Sci Rodolfo Paoletti, Via Balzaretti 9, I-20133 Milan, Italy
来源
关键词
PI3K; Akt; aerobic glycolysis; Warburg effect; cancer metabolism; GLYCOGEN-SYNTHASE KINASE-3; AKT-MEDIATED PHOSPHORYLATION; AEROBIC GLYCOLYSIS; UP-REGULATION; HEXOKINASE; NUCLEOTIDE-METABOLISM; MAMMALIAN TARGET; DOWN-REGULATION; CELL-MIGRATION; MYC;
D O I
10.7150/ijbs.89942
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Aberrant activation of the PI3K/Akt pathway commonly occurs in cancers and correlates with multiple aspects of malignant progression. In particular, recent evidence suggests that the PI3K/Akt signaling plays a fundamental role in promoting the so-called aerobic glycolysis or Warburg effect, by phosphorylating different nutrient transporters and metabolic enzymes, such as GLUT1, HK2, PFKB3/4 and PKM2, and by regulating various molecular networks and proteins, including mTORC1, GSK3, FOXO transcription factors, MYC and HIF-1 alpha . This leads to a profound reprogramming of cancer metabolism, also impacting on pentose phosphate pathway, mitochondrial oxidative phosphorylation, de novo lipid synthesis and redox homeostasis and thereby allowing the fulfillment of both the catabolic and anabolic demands of tumor cells. The present review discusses the interactions between the PI3K/Akt cascade and its metabolic targets, focusing on their possible therapeutic implications.
引用
收藏
页码:3113 / 3125
页数:13
相关论文
共 50 条
  • [41] The Effect of Lycopene on the PI3K/Akt Signalling Pathway in Prostate Cancer
    Chen, Jiezhong
    O'Donoghue, Adam
    Deng, Yi-Fu
    Zhang, Bing
    Kent, Fanning
    O'Hare, Tim
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2014, 14 (06) : 800 - 805
  • [42] Drug discovery approaches targeting the PI3K/Akt pathway in cancer
    C Garcia-Echeverria
    W R Sellers
    Oncogene, 2008, 27 : 5511 - 5526
  • [43] PI3K/Akt/mTOR signaling pathway in cancer stem cells
    Fath, Mohsen Karami
    Ebrahimi, Menooa
    Nourbakhsh, Ehsan
    Hazara, Ahmad Zia
    Mirzaei, Ali
    Shafieyari, Saba
    Salehi, Azadeh
    Hoseinzadeh, Mahsa
    Payandeh, Zahra
    Barati, Ghasem
    PATHOLOGY RESEARCH AND PRACTICE, 2022, 237
  • [44] Obesity and pancreatic cancer: Possible role of the PI3K/Akt pathway
    Huang, Xu-Feng
    Chen, Jiezhong
    SURGERY, 2010, 147 (04) : 596 - 596
  • [45] Role of PI3K/AKT pathway in cancer: the framework of malignant behavior
    Jiang, Ningni
    Dai, Qijie
    Su, Xiaorui
    Fu, Jianjiang
    Feng, Xuancheng
    Peng, Juan
    MOLECULAR BIOLOGY REPORTS, 2020, 47 (06) : 4587 - 4629
  • [46] Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
    Polivka, Jiri, Jr.
    Janku, Filip
    PHARMACOLOGY & THERAPEUTICS, 2014, 142 (02) : 164 - 175
  • [47] The Importance of the PI3K/AKT/MTOR Pathway in the Progression of Ovarian Cancer
    Dobbin, Zachary C.
    Landen, Charles N.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (04): : 8213 - 8227
  • [48] Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway
    Bortul, R
    Tazzari, PL
    Billi, AM
    Tabellini, G
    Mantovani, I
    Cappellini, A
    Grafone, T
    Martinelli, G
    Conte, R
    Martelli, AM
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 (05) : 677 - 686
  • [49] Gentiopicroside targets PAQR3 to activate the PI3K/AKT signaling pathway and ameliorate disordered glucose and lipid metabolism
    Xiao, Haiming
    Sun, Xiaohong
    Lin, Zeyuan
    Yang, Yan
    Zhang, Meng
    Xu, Zhanchi
    Liu, Peiqing
    Liu, Zhongqiu
    Huang, Heqing
    ACTA PHARMACEUTICA SINICA B, 2022, 12 (06) : 2887 - 2904
  • [50] Gentiopicroside targets PAQR3 to activate the PI3K/AKT signaling pathway and ameliorate disordered glucose and lipid metabolism
    Haiming Xiao
    Xiaohong Sun
    Zeyuan Lin
    Yan Yang
    Meng Zhang
    Zhanchi Xu
    Peiqing Liu
    Zhongqiu Liu
    Heqing Huang
    ActaPharmaceuticaSinicaB, 2022, 12 (06) : 2887 - 2904